

LICENSING OPPORTUNITY:

Boosting second messengers

a novel approach to stimulate repair in progressive multiple sclerosis

BACKGROUND INFORMATION

Current *therapeutics in multiple sclerosis (MS)* have limited efficacy in preventing the transition towards the progressive phase and are *no longer effective* in the *progressive stage* of the disease.

In *progressive MS*, the central nervous system (CNS) fails to repair MS lesions. There is *no cure* for the over 1 million progressive MS patients worldwide.

Hasselt University and Maastricht University have found a *new target to boost endogenous repair* processes in an animal model for MS





UHASSELT

KNOWLEDGE IN ACTION

COMPELLING RESULTS

Research showed that *selective boosting of second messengers* improves remyelination in vitro and in vivo. We showed a dose dependent increase in *oligodendrocyte differentiation* in vitro into mature myelinating oligodendrocytes. Moreover, in vivo remyelination was supported by an *improvement in cognitive performance* upon increasing cellular second messengers.

The target specificity is selected to *avoid potential emetic side effects*.



KEY FEATURES AND ADVANTAGES

- Induction of *CNS repair* (remyelination) in animal model for MS.
- Effective *target specificity circumventing expected side-effects*
- *Applications* include demyelinating diseases in general (e.g. progressive MS, X-ALD, PML, spinal cord injury).
- Hasselt University and Maastricht University have *IPR* for boosting remyelination in progressive MS.

MARKET POTENTIAL

The *yearly* average *cost* for a progressive MS patient is calculated on *\$40k*; with more than 1 million patients this renders the *global annual costs* on *>\$40b*.

No cure or treatment is available for secondary progressive MS patients.

For the *alternative disease indications*, there is a prevalence of at least *0.5 million patients worldwide*.

In 2015, the progressive MS alliance determined the *expected yearly revenue* for a treatment for progressive MS on *\$3b*.

OUTSTANDING OPPORTUNITY

Patent application is available for licensing.

Both universities are searching interested parties to complete development and commercialization.

BUSINESS DEVELOPER

An Voets, PhD
UHasselt - Biomedical Research Institute

T +32 (0) 497 06 75 34

an.voets@uhasselt.be